Granules India CFO Sandip Neogi resigns

The company is in the process of appointing a new CFO.

Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr

The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track

Granules India inaugurated water tank at Bonthapally village

The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.

Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets

Granules India received ANDA approval for Guaifenesin and Pseudoephedrine Hydrochloride ER

Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).

Granules India chooses Veeam to protect digital business

Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours

Granules Pharmaceuticals clears USFDA audit

This is the sixth successful USFDA audit for this facility

Granules India Q3FY22 PAT at Rs 100.88 cr.

Granules India has reported consolidated financial results for the period ended December 31, 2021

Granules receives ANDA approval for anti-depressant medication

It has a total of 50 ANDA approvals from USFDA

Granules Pharmaceuticals concludes USFDA audit with three minor observations

The audit is a PAI for two of its product applications filed from this facility